The honest, plain-English guide to GLP-1 medications — what they do, who they help, and what nobody tells you.
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are the most significant development in weight loss medicine in a generation. They're also widely misunderstood. This guide gives you the information you need to have an informed conversation with your doctor.
This ebook is for educational purposes only. It is not medical advice and does not replace a conversation with your physician. GLP-1 medications are prescription drugs. Eligibility, dosing, monitoring, and safety depend on your individual health profile. Always consult your doctor before starting, stopping, or changing any medication.
In 2021, the FDA approved semaglutide (Wegovy) for chronic weight management. The clinical trial results were unlike anything seen before in obesity medicine — participants lost an average of 15-17% of body weight over 68 weeks.
GLP-1 receptor agonists work by mimicking a hormone your body naturally produces after eating. They slow gastric emptying, signal fullness to the brain, reduce appetite, and appear to change how the brain relates to food at a neurological level. People on these medications often report that food simply stops being as compelling. The constant background noise of food thoughts quiets down. For many people who have struggled with weight their entire lives, this is a categorically new experience.
None of this makes them right for everyone. Side effects are real. The cost is significant. What happens when you stop matters enormously. This guide covers all of it.
"GLP-1 medications don't work despite your lifestyle. They work best because of it."
Popcycle · Weight Loss & FitnessGLP-1 is a hormone secreted by your intestines in response to food. GLP-1 receptor agonists bind to these same receptors and activate them continuously — producing sustained appetite suppression, reduced food cravings, and slowed digestion. Tirzepatide also activates GIP receptors, which appears to enhance the effect further.
The GLP-1 class has expanded rapidly. Understanding the differences matters for your conversation with your doctor.
The most studied GLP-1 medication for weight loss. Ozempic (lower dose) is FDA-approved for Type 2 diabetes. Wegovy (higher dose) is FDA-approved specifically for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition. The STEP trials showed average weight loss of 14.9-17.4% over 68 weeks. Administered as a weekly subcutaneous injection, with doses titrated up over 16-20 weeks.
A dual GIP/GLP-1 receptor agonist — it activates two pathways simultaneously. Mounjaro is approved for Type 2 diabetes; Zepbound is approved for weight management. The SURMOUNT trials showed average weight loss of 20.9-22.5% at the highest dose — the largest weight loss seen in any non-surgical clinical trial. Also a weekly injection. Many endocrinologists now consider it the most effective option available.
The first GLP-1 approved for weight management, requiring daily injection rather than weekly. Average weight loss in trials was 5-8% — meaningful but lower than newer options. Less commonly prescribed as first-line now that weekly options with better efficacy exist, but may be appropriate as an alternative or for cost reasons.
An oral form of semaglutide, currently FDA-approved only for Type 2 diabetes. Produces less weight loss than injectable semaglutide due to lower oral bioavailability. Some physicians prescribe off-label for weight management, particularly for patients who prefer not to inject. An oral weight-loss-specific approval at higher doses has been submitted to the FDA.
FDA approval criteria are the starting point, not the full picture. Your physician will assess your complete health profile before prescribing.
For weight management (Wegovy/Zepbound): adults with BMI ≥30, OR adults with BMI ≥27 who also have at least one weight-related condition such as Type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea. Off-label prescribing exists outside these parameters.
Contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not recommended during pregnancy or breastfeeding. People with a history of pancreatitis or severe GI conditions require careful evaluation.
Most common: nausea, vomiting, diarrhea, constipation, and stomach discomfort. Most pronounced when starting and when increasing doses, typically diminishing significantly over time. Serious but less common: pancreatitis (rare), gallbladder disease (more common than previously recognized), and injection site reactions.
Roughly 25-40% of weight lost on GLP-1 medications is lean mass (muscle), not fat — similar to other calorie-deficit methods but worth taking seriously. This is one of the strongest arguments for combining these medications with resistance training and adequate protein intake. People who lose significant muscle mass may find weight regain easier when they eventually stop.
Studies show the majority of people regain most lost weight within 1-2 years of stopping GLP-1 medications, because obesity is a chronic condition driven by biology — and the medication addresses it as long as it's taken. The "I'll take it to lose the weight and then stop" mental model is not well-supported by the evidence.
"These medications are tools. Powerful, validated, genuinely useful tools. What you build with them — the habits, the fitness, the relationship with food — is what lasts."
The gap between clinical evidence and real-world access is one of the most frustrating aspects of GLP-1 medications. Here's the current landscape.
Without insurance, brand-name GLP-1 medications cost $900-$1,400 per month in the U.S. Insurance coverage varies enormously: Medicare Part D currently does not cover weight-loss medications, many commercial plans don't cover them, and employer-sponsored plans are highly variable. Savings programs from manufacturers can significantly reduce costs for commercially insured patients.
A number of telehealth platforms now specialize in GLP-1 prescribing — connecting patients with licensed physicians online, often at lower cost than traditional referrals. Calibrate, Ro Body, Found, and Sequence are among the established platforms. These vary in quality, monitoring intensity, and lifestyle support. Popcycle has reviewed the major platforms in our Weight Loss & Fitness section with PopScores.
If your PCP hasn't brought up GLP-1 medications and you think you may be a candidate, bring it up directly. Come prepared: know your BMI, mention weight-related conditions, and ask specifically about semaglutide or tirzepatide. An endocrinologist or obesity medicine specialist may be a better starting point if your PCP is hesitant.
GLP-1 medications represent a genuine advance in weight science. Whether they're right for you depends on your health profile, your goals, and a real conversation with your physician. Popcycle's Weight Loss & Fitness section reviews the major telehealth platforms and GLP-1 programs — with PopScores based on outcomes, not commission rates.
Explore Popcycle.online